drugset / Trial / NCT02350543

Peri-operative Aspirin Continuation Versus Discontinuation

NCT02350543 ↗

Phase 4 Terminated 50 enrolled Rabin Medical Center
RandomizedParallel-groupOpen-labelTreatment

Summary

This study evaluates the continuation (non-discontinuation) of Aspirin during TURBT. Half of participants will continue their usual low-dose Aspirin regimen during TURBT and throughout the perioperative period, while the other half will discontinue Aspirin use ten days prior to surgery (standard recommendation) and restart therapy two weeks post-discharge.

Timeline

Start
2015-02
Primary completion
2017-06
Completion
2017-06

Outcome

Outcome not reported

Stopped (Enrollment): “Insufficient recruitment.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 75 mg —
Comparator Aspirin Small molecule 100 mg —